Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial

By sjmartinez • September 10, 2024

Evering TH, Moser C, Jilg N, Ritz J, Wohl DA, Li JZ, Margolis D, Javan AC, Eron JJ, Currier JS, Daar ES, Smith DM, Hughes MD, Chew KW; ACTIV-2/A5401 Study Team. Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial. EClinicalMedicine. 2024 Aug 16;75:102787. doi: 10.1016/j.eclinm.2024.102787. PMID: 39252866; PMCID: PMC11381616.

Tags: Clinical Trial, covid-19, Harbor UCLA, Infectious Diseases, long COVID, Monoclonal antibodies, outpatient treatment, PASC, Post COVID conditions, Post-acute sequelae of SARS-CoV-2 infection, Publications

Semaglutide and kidney function: direct kidney protection or an artifact?

Ayoub I, Wong G, Glassock RJ. Semaglutide and kidney function: direct kidney protection or an artifact? Kidney Int. 2024 Nov 18:S0085-2538(24)00793-2. doi: 10.1016/j.kint.2024.11.003. Epub ahead[...]

Moving on from clinical animal-derived surfactants to peptide-based synthetic pulmonary surfactant

Walther FJ, Waring AJ. Moving on from clinical animal-derived surfactants to peptide-based synthetic pulmonary surfactant. Am J Physiol Lung Cell Mol Physiol. 2024 Dec 1;327(6):L883-L889.[...]

Influence of Thyroglobulin Autoantibodies on Thyroglobulin Levels Measured by Different Methodologies: IMA, LC-MS/MS, and RIA

Petrovic I, LoPresti J, Fatemi S, Gianoukakis A, Burman K, Gomez-Lima CJ, Nguyen CT, Spencer CA. Influence of Thyroglobulin Autoantibodies on Thyroglobulin Levels Measured by[...]